New biomarkers for diagnosis and management of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women. Even though the definition of PCOS has changed over the years, all diagnostic criteria include two or more of the following: oligomenorrhea/oligoovulation/anovulation, androgen excess and polycystic ovaries...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2017-08, Vol.471, p.248-253
Main Author: Karakas, Sidika E.
Format: Article
Language:English
Subjects:
Anti-Mullerian hormone
Biomarkers - analysis
Biomarkers - metabolism
Female
Glycated Hemoglobin A - analysis
Glycated Hemoglobin A - metabolism
Humans
Polycystic ovary syndrome
Polycystic Ovary Syndrome - diagnosis
Polycystic Ovary Syndrome - metabolism
Polycystic Ovary Syndrome - therapy
Sex hormone binding globulin
Sex Hormone-Binding Globulin - analysis
Sex Hormone-Binding Globulin - metabolism
Testosterone - analysis
Testosterone - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women. Even though the definition of PCOS has changed over the years, all diagnostic criteria include two or more of the following: oligomenorrhea/oligoovulation/anovulation, androgen excess and polycystic ovaries (PCO). Traditional method of assessing the ovarian morphology has been transvaginal pelvic ultrasound. Recent studies support that serum anti-Mullerian hormone (AMH) levels correlate with the number of ovarian follicles and cysts. Hence, measurement of AMH is adequate to make the diagnosis. Traditionally, hyperandrogenemia has been assessed by measuring total-testosterone. The literature stresses the importance of sex hormone binding globulin (SHBG) measurements and bioavailable-testosterone and free-testosterone calculations, because insulin resistance decreases SHBG, lowers total-testosterone, and leads to under-estimation of bioavailable- and free-testosterone. Since 50–60% of PCOS patients have metabolic syndrome, assessment of metabolic risk is also necessary. It is important to diagnose insulin resistance before development of glucose intolerance and diabetes. This requires measurements of not only plasma glucose but also insulin concentrations. Determination of HgBA1 can be informative as well. This review aims to present an accurate and cost-effective approach to diagnosis and management of PCOS. •Anti-Mullerian (AMH) measurement may be replacing transvaginal pelvic ultrasound for diagnosis of polycystic ovaries.•Measurement of total testosterone alone is insufficient and can be misleading for assessment of hyperandrogenemia.•Measurement of HgBA1c can be informative in assessing metabolic risk.
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2017.06.009